1352. Deputy Albert Dolan asked the Minister for Health the rationale for excluding evorel 100mcg patches from the new hormone replacement therapy (HRT) scheme, given its widespread use as a substitute for estradot, which has been in long-term short supply; the measures being taken to ensure continuity of HRT care for those impacted by the supply shortages of estradot, including the potential inclusion of alternatives such as evorel in the scheme; and if her Department or the HSE is reviewing the classification or coverage of unlicensed but clinically necessary HRT alternatives to ensure equitable access to treatment for all women. [29291/25]

Summary

1352. Deputy Albert Dolan asked the Minister for Health the rationale for excluding evorel 100mcg patches from the new hormone replacement therapy (HRT) scheme, given its widespread use as a substitute for estradot, which has been in long-term short supply; the measures being taken to ensure continuity of HRT care for those impacted by the supply shortages of estradot, including the potential inclusion of alternatives such as evorel in the scheme; and if her Department or the HSE is reviewing the classification or coverage of unlicensed but clinically necessary HRT alternatives to ensure equitable access to treatment for all women. [29291/25]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 10 June 2025

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.